


PHARMACEUTICAL 2017

ESPERION[®]

Esperion Therapeutics Inc. Rank 91 of 313







PHARMACEUTICAL 2017

ESPERION

Esperion Therapeutics Inc. Rank 91 of 313

The relative strengths and weaknesses of Esperion Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Esperion Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 246% points. The greatest weakness of Esperion Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 69% points.

The company's Economic Capital Ratio, given in the ranking table, is -40%, being 377% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	213,577
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	15,589
Liabilities, Non-Current	1,022
Other Assets	30,962
Other Compr. Net Income	310
Other Expenses	376
Other Liabilities	0
Other Net Income	1,548
Property and Equipment	674
Research and Development	57,868
Revenues	0
Selling, General and Administrative Expense	18,282

Output Variable	Value in 1000 USD
Assets	245,213
Liabilities	16,611
Expenses	76,526
Stockholders Equity	228,602
Net Income	-74,978
Comprehensive Net Income	-74,823
Economic Capital Ratio	-40%

